ArticleProbiotics and antimicrobial proteins2026
Design and Evaluation of the Antibacterial Peptide FK18: a Therapeutic Approach for Mastitis in Dairy Animals.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Natural and Synthetic AMPs from Latin America across Diversity Engineering and Applications.ACS infectious diseases · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rising prevalence of antimicrobial resistance (AMR) among microorganisms is a global health and economic concern with major implications for livestock, as traditional antibiotics lose efficacy and novel agents with distinct mechanisms of action are required. Mastitis, an inflammation of the mammary gland mainly caused by bacterial infections, affects dairy cows and sheep, impairing milk quality, reducing production, and generating economic losses. This study introduces FK18, a synthetic antimicrobial peptide (AMP) designed with bioinformatics tools, which showed potent antibacterial activity against mastitis-associated pathogens. Minimum inhibitory concentration (MIC) values were 5 µM for Staphylococcus aureus (bovine milk isolate) and 10 µM for Escherichia coli (ovine milk isolate). The antibacterial activity of FK18 was confirmed through multiple assays. Time-kill and membrane permeabilization studies demonstrated rapid bactericidal action, with near-complete reduction of CFU within 15 min for S. aureus and 120 min for E. coli (p < 0.05), which is consistent with disruption of the bacterial cell membrane. FK18 exhibited low toxicity toward eukaryotic cells, with an IC₅₀ of 21.46 µM in RAW 264.7 macrophages, and caused only 20% mortality in Galleria mellonella larvae at 100 µM. The peptide also remained stable under physiological saline conditions. Strong synergistic effects were observed with ciprofloxacin, with fractional inhibitory concentration index (FICI) values of 0.24 (S. aureus) and 0.01 (E. coli). By targeting bovine and ovine mastitis, this study highlights FK18 as a promising candidate to reduce antibiotic use in dairy animals and to support peptide-based therapeutic strategies in veterinary medicine.
Indexed as
Identifiers
41134484What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.